Sildenafil Tablet, Film Coated
Product Images NDC 71335-2657

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 71335-2657). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 02)

FDA Label Image

4 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 05)

4 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 05)
This is a summary table showing changes from baseline in meters at different time points during a study. It compares the effect of different dosages of Sildenafil (20mg, 40mg, and 80mg three times a day) with a placebo. The data is specified for weeks 4, 8, and 12 of the study.*
FDA Label Image

5 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 06)

5 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 06)
This text appears to contain information related to a medical study involving the use of Placebo and Sildenafil 20 mg TID in patients with Idiopathic PAH. It includes data on baseline walk distance, PH criteria, function capacity, Gender, Age, Mean PAP, dynessec/omim, and placebo-corrected change in 6-Minute Walk Distance. The study may have evaluated the efficacy and impact of Sildenafil on patients with Idiopathic PAH.*
FDA Label Image

Pi Logo (55aa9711 6df5 4516 Bf00 A1acf7f7a464 09)

FDA Label Image

Logo (55aa9711 6df5 4516 Bf00 A1acf7f7a464 10)

Logo (55aa9711 6df5 4516 Bf00 A1acf7f7a464 10)
Not available.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
This text provides recommendations for drug interactions with Atorvastatin, Azithromycin, Bosentan, Cimetidine, Penicillin, Erythromycin, Oral Contraceptives, Ritonavir, and Saquinavir. It also mentions that no dose adjustment is needed for Atorvastatin, Azithromycin, Penicillin, Oral Contraceptives, Erythromycin, and Saquinavir. Additionally, it mentions concerns about coadministration with Bosentan, Ritonavir, and the interaction of Sildenafil with bosentan therapy and its impact on exercise capacity.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
This is a list that provides recommendations for drug interactions based on reported drug fold change and 90% confidence interval. It specifies whether dose adjustment is needed or not for various drugs like Acenocoumarol, Aspirin, Bosentan, Doxazosin, Ethinylestradiol, Lovonorgestrel, Phenprocoumon, Ritonavir, Saquinavir, and Tolbutamide. It also includes a graph showing changes relative to interacting drugs alone. Note that no benefit on exercise capacity has been observed when Sildenafil is added to Bosentan therapy.*
FDA Label Image

Figure-5 (Figure 5)

FDA Label Image

Label (Lbl713352657)

Label (Lbl713352657)
This text describes a medication containing Sildenafil, with each film-coated tablet equivalent to 20 mg of Sildenafil. It provides storage instructions, reminding to keep it out of reach of children and store in a tight, light-resistant container at 20°C to 25°C. The dosage information is for adults and advises scanning the package insert QR code for full prescribing and patient information. The medication is manufactured by Bryant Ranch Prepack, Inc. and distributed by Torrent Pharmaceuticals Ltd.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.